Quantcast

Latest Postherpetic neuralgia Stories

2014-09-05 16:23:02

NEWARK, Calif., Sept. 5, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that Judge Kentaji Brown Jackson of the federal district court for the District of Columbia has granted Depomed's motion for summary judgment in the company's lawsuit against the United States Food and Drug Administration seeking an order requiring the FDA to grant Gralise(®) (gabapentin) Orphan Drug exclusivity for the management of postherpetic neuralgia (PHN). The court's ruling requires...

2014-08-25 16:27:20

NEWARK, Calif., Aug. 25, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Morgan Stanley 2014 Global Healthcare Conference in New York City. The presentation at the Morgan Stanley conference is scheduled for 2:40 pm ET (11:40 am PT) on Wednesday September 10, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast...

2014-08-19 12:28:53

NEWARK, Calif., Aug. 19, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation lawsuit against Actavis, Inc. related to Actavis's Abbreviated New Drug Application for generic versions of Depomed's Gralise(®) (gabapentin) tablets for the management of postherpetic neuralgia. Judge Pisano's ruling finds that Actavis infringes all...

2014-08-11 08:30:05

All studies on track for completion and final study reports by November 2014 MALVERN, Pa., Aug. 11, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has completed patient enrollment for the dermal safety studies and the pivotal pharmacokinetic study related to its investigational product Ztlido (lidocaine patch 1.8%), a...

2014-07-25 16:23:01

NEWARK, Calif., July 25, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release second quarter fiscal year 2014 financial results after the market closes on Wednesday, August 6, 2014. The Company will host a conference call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on...

2014-07-20 23:02:11

ReportsnReports.com adds “Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 202” to its store. Dallas, TX (PRWEB) July 20, 2014 Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic...

2014-07-17 16:26:16

Opinion Expected "In Short Order" NEWARK, Calif., July 17, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that on July 17, 2014, Judge Joel A. Pisano of the United States District Court for the District of New Jersey entered an order preliminarily enjoining Actavis Elizabeth LLC and Actavis Inc. from marketing a generic version of Gralise® (gabapentin) prior to the Court's issuance of an opinion in the matter. The order indicates the Court expects to issue an...

2014-07-14 12:27:21

The Company expects the studies, along with the PK study, to be completed in the 4th quarter of 2014 MALVERN, Pa., July 14, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has commenced dermal safety studies of its Ztlido (lidocaine patch 1.8%) product candidate, a next-generation branded lidocaine patch for the treatment of...

2014-06-18 08:28:42

NEWARK, Calif., June 18, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities 2014 Healthcare Conference in New York City. The presentation at the JMP conference is scheduled for 11:30 am ET (8:30 am PT) on Tuesday June 24, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30...

2014-06-10 08:30:40

NEWARK, Calif., June 10, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Wells Fargo 2014 Healthcare Conference in Boston. The presentation at the Wells Fargo conference is scheduled for 3:35 pm ET (12:35 pm PT) on Wednesday June 18, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30...


Latest Postherpetic neuralgia Reference Libraries

69_7b87211f9314eacab994d465558a3a1b
2011-01-24 12:56:26

Herpes zoster (or zoster), is known as shingles or zona and is a viral disease characterized by painful skin rash with blisters in a limited area on one side of the body. Initial infection causes chickenpox. Once chickenpox is over the virus remains in the body and can cause shingles. It can become latent in the nerve cell bodies and sometimes in the dorsal root, cranial nerve, or autonomic ganglion. Years after initial infection, another breakout can cause a painful rash. The rash usually...

More Articles (1 articles) »
Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'